Allergy specialist Stallergenes taps Aptar for digital delivery
allergy, Aptar, digital, digital health, immunotherapy, non-adherence, Stallergenes Greer
0 Comment
non-adherence
Non-adherence: pharma’s final financial frontier
adherence, Deep Dive, medicines adherence, non-adherence, patient centricity
0 Comment
No other industry would tolerate avoidable annual losses of $637 billion, but that’s exactly what pharma is doing by not investing in adherence. Now is the time to start recovering that revenue.